Connex Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.90 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.00 Cr
as on 16-11-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 96.13 Cr
as on 16-11-2024
- Revenue 33.03%
(FY 2023)
- Profit 18.45%
(FY 2023)
- Ebitda 12.12%
(FY 2023)
- Net Worth 113.92%
(FY 2023)
- Total Assets 19.01%
(FY 2023)
About Connex Pharma
The Corporate was formerly known as Vijayasri Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.90 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹96.13 Cr.
Desireddy Venkata, Parimi Prasanna, and Koushik Parimi serve as directors at the Company.
- CIN/LLPIN
U24232AP2014PTC094952
- Company No.
094952
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Connex Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parimi Prasanna  | Managing Director | 27-Jul-2018 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Koushik Parimi | Director | 27-Jul-2018 | Current |
| Desireddy Venkata | Director | 08-Jan-2024 | Current |
Financial Performance of Connex Pharma.
Connex Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 33.03% increase. The company also saw a substantial improvement in profitability, with a 18.45% increase in profit. The company's net worth Soared by an impressive increase of 113.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Connex Pharma?
In 2023, Connex Pharma had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Nov 2024 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 May 2024 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 May 2024 | ₹1.93 Cr | Open |
How Many Employees Work at Connex Pharma?
Unlock and access historical data on people associated with Connex Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Connex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Connex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
